Colorectal Cancer Biomarkers
Key Points
Key Points
Current evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR-targeted therapies and conventional chemotherapy regimens were developed through collaboration of four societies: American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).
Diagnosis
...gnosis...
...ectal carcinoma patients being considered for...
...600 (BRAF c. 1799 (p.V600) mutational an...
...0 mutational analysis should be performed in d...
...nicians should order mismatch repair st...
...insufficient evidence to recommend BRAF...
...here is insufficient evidence to recommend PIK3CA...
...re is insufficient evidence to recommend PTEN...
...tastatic or recurrent colorectal carcinoma tissue...
...fixed paraffin embedded tissue is an acceptable s...
...st use validated colorectal carcinoma mol...
...ormance of molecular biomarker testing for col...
...es must validate the performance of IHC te...
...s must provide clinically appropriate tur...
...lar and IHC biomarker testing in colo...
...hould establish policies to ensure e...
...patient’s medical team, including pathol...
...es that require send out of tests for treatm...
...st evaluate candidate specimens fo...
...boratories should use colorectal ca...
...cinoma molecular biomarker results should b...
...ectal carcinoma molecular biomarker testing rep...
...t incorporate colorectal carcinoma molecular bio...
...es of RAS Mutations and Anti-EGFR TherapyH...
...2. Concordance Rates Between Primary and Metasta...